Patient factors associated with the use of methotrexate among children without systemic arthritis (n = 2502).
| Patient Factor | Univariate OR (95% CI) | Multivariable OR (95% CI) |
|---|---|---|
| Extended oligoarthritis* | 7.3 (4.7–11) | 3.8 (2.3–6.3) |
| RF– polyarthritis* | 4.7 (3.7–5.9) | 2.6 (1.9–3.7) |
| RF+ polyarthritis* | 9.5 (5.8–15) | 3.9 (2.2–7.1) |
| Psoriatic arthritis* | 4.5 (2.9–6.8) | 3.5 (2.2–5.5) |
| ERA* | 0.9 (0.7–1.2) | — |
| History ≥ 5 joints | 4.4 (3.7–5.3) | 2.0 (1.5–2.8) |
| HLA-B27 | 0.6 (0.4–0.8) | — |
| Uveitis | 3.5 (2.5–5.0) | 4.4 (3.0–6.5) |
| IBD | 2.1 (1.0–4.4) | 3.4 (1.3–8.6) |
| Sacroiliac tenderness | 0.5 (0.4–0.7) | 0.5 (0.4–0.7) |
| Enthesitis | 0.6 (0.5–0.8) | — |
| Psoriasis rash | 2.0 (1.3–3.1) | — |
| ACPA | 9.9 (4.0–24) | 4.9 (1.9–13) |
| Radiographic damage | 2.3 (1.8–2.9) | 1.8 (1.3–2.4) |
| Disease duration, yrs | 1.1 (1.1–1.2) | 1.1 (1.0–1.1) |
↵* Compared to oligoarthritis category. RF: rheumatoid factor; ERA: enthesitis-related arthritis; IBD: inflammatory bowel disease; ACPA: anticitrullinated protein antibodies.